FY2025 · ended Dec 31, 2025 · Revenue $16.10M, -40.6% YoY · Filed Mar 2, 2026
uniQure N.V. (QURE) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $16.1 million and a net loss of $199.0 million. Free cash flow was -$178.4 million. As of Sep 30, 2026 it held $98.4 million in cash and investments and $62.4 million in total debt.
Revenue (TTM)
$20.17M
+28.0% vs year-ago TTM
Net income (TTM)
$-232.90M
Operating cash flow (TTM)
$-192.22M
-25.4% vs year-ago TTM
Free cash flow (TTM)
$-192.96M
-25.6% vs year-ago TTM
EPS (TTM)
$-3.57
Dividend per share
None
Shares outstanding
62.53M
+15.6% vs prior year
Net cash
$36.08M
as of Sep 30, 2026
Operating margin
-1001.7%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- QURE (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Amsterdam
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1590560
- Former names
- uniQure B.V. (until Feb 6, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $16.1M | $27.1M | $15.8M | $106.5M | $524.0M |
| Operating income | -$185.3M | -$184.3M | -$282.9M | -$143.2M | $310.6M |
| Net income | -$199.0M | — | — | — | — |
| Diluted EPS | -$3.46 | -$4.92 | -$6.47 | -$2.71 | $7.04 |
| Operating cash flow | -$178.0M | -$182.7M | -$145.9M | -$145.1M | $288.0M |
| Free cash flow | -$178.4M | -$186.1M | -$153.1M | -$162.7M | $270.5M |
| Total assets | $824.9M | $556.5M | $831.7M | $705.0M | $809.2M |
| Total liabilities | $626.0M | $563.3M | $624.0M | $229.0M | $213.4M |
| Stockholders' equity | $198.9M | -$6.8M | $207.7M | $476.0M | $595.8M |
| Cash and investments | $80.2M | $158.9M | $241.4M | $228.0M | $556.3M |
| Total debt | $85.6M | $80.8M | $184.2M | $184.6M | $170.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 2, 2026 | Oct 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 29, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 2, 2026 | Sep 2, 2026 |
| 10-Q | Quarterly report | Jul 29, 2026 | Jun 30, 2026 |
All 953 uniQure N.V. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.